Controlling Influences of Oxygen Tension and CD26/DPP4 Enzymatic Activity on Regulation of Hematopoietic Stem/Progenitor Cells and Hematopoiesis During Health, Ageing, and Disease
Controlling Influences of Oxygen Tension and CD26/DPP4 Enzymatic Activity on Regulation of Hematopoietic Stem/Progenitor Cells and Hematopoiesis During Health, Ageing, and Disease
批准号:
10219824
负责人:
HAL E. BROXMEYER
金额:
$76.81万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-05-01 至 2022-04-30
关键词:
AddressAgingAirAnimal ModelBasic ScienceBlood CellsBone MarrowCCL3 geneCSF3 geneCXCL12 geneCell Culture TechniquesCell CycleCell modelCell surfaceCellsClinical InvestigatorCollaborationsCollectionControlled EnvironmentDipeptidyl-Peptidase IVDiseaseEngraftmentFundingGene ExpressionGoalsGrantGranulocyte-Macrophage Colony-Stimulating FactorHealthHealth BenefitHematopoiesisHematopoieticHematopoietic stem cellsHeterogeneityHumanHypoxiaIL3 GeneLaboratoriesMalignant - descriptorMetabolismMethodologyMusNational Heart, Lung, and Blood InstituteNon-MalignantOxygenPatientsPhenotypePhysiologicalPlayProceduresProcessReactive Oxygen SpeciesRecoveryRegenerative MedicineRegulationRoleRunningShockSourceStressSystemTherapeuticTimeTranslatingTreatment EfficacyUmbilical Cord BloodUnited States National Institutes of Healthcell typechemokinecytokinehematopoietic cell transplantationin vivoinnovationinsightpersonalized medicinepre-clinicalprotein expressionreceptor bindingresponsestemstem cell functionstem cells
中文摘要
虽然我们对造血干细胞(HSC)和祖细胞(HPC)的表型(细胞表面和细胞结构)了解甚多
英文摘要
While much is known about hematopoietic stem (HSC) and progenitor cell (HPC) phenotype (cell surface and
intracellular markers), heterogeneity, and function, there is still more to be learned, especially for how best to
use and manipulate these cells for therapeutic advantage. The PI has run a continuously NIH-funded basic
science laboratory for over 39 years. His goal continues to be to translate mechanistic insight for pre-clinical
cell and animal models, and in collaboration with clinical investigators for clinical utility. The purpose of this NIH
R35 application is to allow the PI and his lab ample uninterrupted time to pursue new ideas and creative
approaches in context of two active NHLBI R01 grants. HL 056416 focuses on oxygen tension, metabolism,
function and optimal collection and activities of HSCs from bone marrow (BM) and cord blood (CB), findings
with implications for other stem and progenitor cell types. Exposure of mouse BM or human CB cells to
ambient air within minutes induces Extra Physiological Shock Stress (EPHOSS), causing loss of HSCs through
Reactive Oxygen Species (ROS) induced differentiation, not cell death. EPHOSS may have implications for
personalized medicine to more accurately evaluate gene expression profiles and cell responsiveness in
situations more closely related to O2 tension of cells in their in vivo microenvironment, compared to cells
collected/processed in an artificial environment of ambient air. HL 112669 assesses effects of
CD26/Dipeptidylpeptidase (DPP)4 in truncating selected cytokines (e.g. GM-CSF, G-CSF, IL-3, EPO, TPO)
and chemokines (e.g. CXCL12, CCL3), thus changing their receptor-binding, cellular and intracellular activities.
This has relevance to all systems in which cytokines/chemokines play a regulatory role. Blocking EPHOSS or
inhibiting CD26/DPP4 enzymatic activity results in collection of increased numbers of HSCs. We will produce
new information on mechanistic regulation of hematopoiesis. Our hypotheses and significance are:
understanding EPHOSS and enzymatic activities of DPP4 and their manipulation will lead to a better
understanding of HSC/HPC functions in health, ageing, and disease, information that can be used to
accelerate patient recovery from stress/disease and for human CB hematopoietic cell transplantation (HCT).
Our goals are to determine: 1) what hypoxic collection, processing, cell culture, and in vivo engraftment, and
DPP4 inhibition, informs us about the regulation of HSCs, HPCs, and hematopoiesis during health, in response
to stress, ageing and disease; 2) other means to compensate for effects of EPHOSS for more efficient HCT,
and 3) differences in cell cycle status and gene and protein expression profile of HSCs and HPCs
collected/processed in hypoxia/air and/or -/+ DPP4 inhibition. The innovation lies in paradigm changing
concepts to be addressed with state-of-the-art methodologies. What we find can be translated to other cell
sources for HCT, and for cells/procedures in the emerging field of regenerative medicine to enhance treatment
efficacy.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1056/nejmoa2027372
发表时间:
2021-01-07
期刊:
The New England journal of medicine
影响因子:
--
作者:
[Farag SS, Abu Zaid M, Schwartz JE, Thakrar TC, Blakley AJ, Abonour R, Robertson MJ, Broxmeyer HE, Zhang S]
通讯作者:
Zhang S
DEK Regulation of Hematopoietic Stem Cell Renewal, Fate, and Hematopoiesis
-
批准号:9476237
-
项目类别:
-
资助金额:$49.9万
-
财政年份:2016
-
负责人:HAL E. BROXMEYER
-
依托单位:
Administrative Core
-
批准号:10473853
-
项目类别:
-
资助金额:$7.51万
-
财政年份:2015
-
负责人:HAL E. BROXMEYER
-
依托单位:
Hypoxia Core
-
批准号:10473863
-
项目类别:
-
资助金额:$13.67万
-
财政年份:2015
-
负责人:HAL E. BROXMEYER
-
依托单位:
Hypoxia Core
-
批准号:10681262
-
项目类别:
-
资助金额:$14.29万
-
财政年份:2015
-
负责人:HAL E. BROXMEYER
-
依托单位:
Hematopoietic stem and progenitor cell regulation for enhanced clinical efficacy
-
批准号:10201069
-
项目类别:
-
资助金额:$23.95万
-
财政年份:2015
-
负责人:HAL E. BROXMEYER
-
依托单位:
Hematopoietic stem and progenitor cell regulation for enhanced clinical efficacy
-
批准号:9987195
-
项目类别:
-
资助金额:$1.97万
-
财政年份:2015
-
负责人:HAL E. BROXMEYER
-
依托单位:
Administrative Core
-
批准号:10206538
-
项目类别:
-
资助金额:$15.44万
-
财政年份:2015
-
负责人:HAL E. BROXMEYER
-
依托单位:
Hypoxia Core
-
批准号:10206541
-
项目类别:
-
资助金额:$15.44万
-
财政年份:2015
-
负责人:HAL E. BROXMEYER
-
依托单位:
Hematopoietic stem and progenitor cell regulation for enhanced clinical efficacy
-
批准号:9752987
-
项目类别:
-
资助金额:$91.95万
-
财政年份:2015
-
负责人:HAL E. BROXMEYER
-
依托单位:
Administrative Core
-
批准号:10681256
-
项目类别:
-
资助金额:$7.85万
-
财政年份:2015
-
负责人:HAL E. BROXMEYER
-
依托单位:
Hematopoietic stem and progenitor cell regulation for enhanced clinical efficacy
-
批准号:9325311
-
项目类别:
-
资助金额:$94.85万
-
财政年份:2015
-
负责人:HAL E. BROXMEYER
-
依托单位:
Hematopoietic stem and progenitor cell regulation for enhanced clinical efficacy
-
批准号:8972225
-
项目类别:
-
资助金额:$99.53万
-
财政年份:2015
-
负责人:HAL E. BROXMEYER
-
依托单位:
Enhancing Engraftment of Cord Blood by CD26 Inhibition
-
批准号:8670014
-
项目类别:
-
资助金额:$72.7万
-
财政年份:2012
-
负责人:HAL E. BROXMEYER
-
依托单位:
Enhancing Engraftment of Cord Blood by CD26 Inhibition
-
批准号:8424273
-
项目类别:
-
资助金额:$71.61万
-
财政年份:2012
-
负责人:HAL E. BROXMEYER
-
依托单位:
Enhancing Engraftment of Cord Blood by CD26 Inhibition
-
批准号:8813618
-
项目类别:
-
资助金额:$72.03万
-
财政年份:2012
-
负责人:HAL E. BROXMEYER
-
依托单位:
Enhancing Engraftment of Cord Blood by CD26 Inhibition
-
批准号:8219617
-
项目类别:
-
资助金额:$76.06万
-
财政年份:2012
-
负责人:HAL E. BROXMEYER
-
依托单位:
Regulating hematopoietic stem cells and hematopoiesis for clinical efficacy
-
批准号:8505009
-
项目类别:
-
资助金额:$70.75万
-
财政年份:2010
-
负责人:HAL E. BROXMEYER
-
依托单位:
Regulating hematopoietic stem cells and hematopoiesis for clinical efficacy
-
批准号:8296358
-
项目类别:
-
资助金额:$75.02万
-
财政年份:2010
-
负责人:HAL E. BROXMEYER
-
依托单位:
Regulating hematopoietic stem cells and hematopoiesis for clinical efficacy
-
批准号:8150918
-
项目类别:
-
资助金额:$71.74万
-
财政年份:2010
-
负责人:HAL E. BROXMEYER
-
依托单位:
Regulating hematopoietic stem cells and hematopoiesis for clinical efficacy
-
批准号:8704528
-
项目类别:
-
资助金额:$3.22万
-
财政年份:2010
-
负责人:HAL E. BROXMEYER
-
依托单位:
海外基金